Physician profile
Sherry Li
NPI 1326784828
$3,070.59
in general payments reported to CMS, 2019-2025
14 companies · $3,042 in 2025
The $3,042 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $28.55 · 2025: $3,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,877 · Grant: $1,000 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,876.93 |
| Grant | $1,000.00 |
| Education | $193.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,294.47 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $411.07 | 2025 | Tezspire, Breztri, Fasenra |
| Csl Behring | $286.78 | 2024-2025 | Andembry, Hizentra, Haegarda |
| Pharming Healthcare, INC. | $181.74 | 2025 | Ruconest |
| Amgen INC. | $156.46 | 2025 | Actimmune |
| Takeda Pharmaceuticals U.S.A., INC. | $143.25 | 2025 | Takhzyro |
| Regeneron Healthcare Solutions, INC. | $126.22 | 2025 | Dupixent |
| Glaxosmithkline, LLC. | $115.62 | 2025 | Nucala |
| Sanofi-Aventis U.S. LLC | $99.00 | 2025 | |
| Octapharma USA, INC. | $79.66 | 2025 | Panzyga, Octagam Immune Globulin (Human) |
| Biocryst US Sales Co., LLC | $65.27 | 2025 | Orladeyo |
| Genentech USA, INC. | $52.41 | 2025 | Xolair |
| Invivyd INC | $42.94 | 2025 | Pemgarda |
| Grifols USA, LLC | $15.70 | 2025 | Gamunex-C |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.